Results from the first rigorous clinical trial of the bird flu vaccine for humans suggest that existing manufacturing methods could not produce enough vaccine to protect most Americans.
Office of Strategic Communication
Results from the first rigorous clinical trial of the bird flu vaccine for humans suggest that existing manufacturing methods could not produce enough vaccine to protect most Americans.